Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience

INTRODUCTION: Eslicarbazepine acetate was first approved in the European Union in 2009 as adjunctive therapy in adults with partial-onset seizures with or without secondary generalization. OBJECTIVE: The objective of this study was to review the safety profile of eslicarbazepine acetate analyzing th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gama, Helena, Vieira, Mariana, Costa, Raquel, Graça, Joana, Magalhães, Luís M., Soares-da-Silva, Patrício
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688182/
https://www.ncbi.nlm.nih.gov/pubmed/28752473
http://dx.doi.org/10.1007/s40264-017-0576-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688182/
https://www.ncbi.nlm.nih.gov/pubmed/28752473
http://dx.doi.org/10.1007/s40264-017-0576-4

Ejemplares similares